Several OGA inhibitors, including MK-8719 (183), ASN90 (184), ASN51 (185), BIIB113 (186), and LY3372689 (187), have demonstrated favorable safety profiles and brain penetrance in early-phase clinical trials for AD, PD, progressive supranuclear palsy (PSP), and related tauopathies (188). Here, OGA is linked to supranuclear palsy, progressive, 1.